Faricimab玻璃体腔内注射治疗视网膜静脉阻塞的研究进展  

Advances in the treatment of retinal vein occlusion with Faricimab intravitreal injection

作　　者：牛浩宇(综述) 余萍(审校)[1] NIU Haoyu;YU Ping(Department of Ophthalmology,Affiliated Hospital of Qinghai University,Xining 810001,China)

机构地区：[1]青海大学附属医院眼科,西宁810001

出　　处：《眼科学报》2024年第11期586-592,共7页Eye Science

摘　　要：视网膜静脉阻塞(retinal vein occlusion,RVO)是导致视力损害的主要眼底疾病之一,常引发视网膜缺血、出血、液体渗漏和黄斑水肿,从而导致视力下降甚至永久丧失。目前,RVO继发黄斑水肿的主要治疗方法是玻璃体腔内注射抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物。然而,RVO的病理机制不仅限于VEGF,还涉及血管生成素-2(angiopoietin-2,Ang-2)的作用。在病理状态下,Ang-2通过破坏血管稳定性,诱导新生血管形成,并加剧炎症反应,进一步促进RVO的病程进展。法瑞西单抗(Faricimab)作为一种双特异性抗体药物,能够同时抑制VEGF-A和Ang-2这两条关键的病理通路,显示出在改善患者视力方面的潜在优势。文章对Faricimab在RVO治疗中的作用机制、临床应用、相关治疗药物对比及未来发展前景进行了详细论述,为其在眼科领域的进一步应用提供了理论依据和参考。Retinal vein occlusion(RVO)is one of the leading retinal diseases causing vision impairment and is often associated with retinal ischemia,hemorrhage,fluid leakage,and macular edema,ultimately resulting in decreased vision or even permanent vision loss.Currently,the primary treatment for RVO-associated macular edema is intravitreal injection of anti-vascular endothelial growth factor(VEGF)agents.However,the pathological mechanisms of RVO are not limited to VEGF alone,but also involve angiopoietin-2(Ang-2).Under pathological conditions,Ang-2 disrupts vascular stability,induces neovascularization,and exacerbates inflammatory responses,thereby accelerating the progression of RVO.Faricimab,as a bispecific antibody,can simultaneously inhibit both VEGF-A and Ang-2 pathways,which are critical in RVO pathogenesis,and has shown potential advantages in improving visual outcomes.The article provides a detailed discussion on the mechanism of action,clinical applications,comparison with related therapeutic agents,and future development prospects of Faricimab in the treatment of RVO,offering a theoretical basis and reference for its further application in ophthalmology.

关 键 词：法瑞西单抗 视网膜静脉阻塞 血管内皮生长因子 血管内皮生长因子A 血管生成素-2 糖皮质激素 

分 类 号：R774.1[医药卫生—眼科] R543[医药卫生—临床医学]